Navigation Links
Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
Date:4/24/2008

e brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Alan Roemer, Vice President

Investor Relations & Corporate Communications

alan.roemer@pharmasset.com

Office: (609) 613-4125

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that we cannot enroll enough patients for the Phase 3 registration clinical trial for clevudine, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2007 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
2. Pharmasset Receives $10 Million of Working Capital
3. Pharmasset Appoints Herbert J. Conrad as a Director
4. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
5. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
6. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
7. Pharmasset Reports Fiscal Year End 2007 Financial Results
8. Pharmasset Appoints Michael Rogers as Chief Development Officer
9. Pharmasset to Present at Three Investor Conferences in November 2007
10. Pharmasset Accesses up to $30 Million of Working Capital
11. Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... April 16, 2015  Scientists from Cleave Biosciences will ... the Horizon," at the American Association for Cancer Research ... on Sunday, April 19, 2015 from 3:15pm to ... of Biology, will present new in vivo and mechanism ... inhibitor of p97, a critical enzyme that controls various ...
(Date:4/16/2015)... , April 16, 2015  EMD Serono today ... Darmstadt, Germany , appointed ... Head of Global Clinical Development.  Dr. Reicin brings ... experience in Oncology and Immunology. She is an ... served as a Vice President in various capacities ...
(Date:4/16/2015)... Columbia and MENLO PARK, Calif. ... Inc. (OTCQX: DMPI) (DelMar and the Company), a ... therapies in new orphan drug indications, today announced that ... added as a clinical trial site for the ongoing, ... refractory glioblastoma multiforme (GBM), the most common and deadly ...
(Date:4/16/2015)... Md. , April 16, 2015  Northwest ... a biotechnology company developing non-toxic DCVax® personalized immune ... been included in the Loncar Cancer Immunotherapy Index ... investors better track the immunotherapy field within the ... have selected "the top 25 companies" in the ...
Breaking Biology Technology:Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 3Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 2NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 3
... managed, with the help of an advanced X-ray flash, to ... that has been recognised by the journal Science . ... home to one of the world,s most advanced particle accelerators, ... and study life,s tiniest components: atoms, molecules and proteins. ...
... PLYMOUTH MEETING, Pa. , May 10 /PRNewswire-Asia-FirstCall/ -- ... announced,financial results for the first quarter ended March 31, 2010 . ... ... was a,quarter of successful management transition at Sunstone. We replaced senior,managers including ...
... Fla. , May 10 Dyadic International, Inc. ... today that its President and Chief Executive Officer, Mark ... Renshaw 6th Annual Global Healthcare Conference in London, England ... 11:05 a.m. local time ( 6:05 a.m. EDT ). ...
Cached Biology Technology:BMP Sunstone Reports First Quarter 2010 Financial Results 2BMP Sunstone Reports First Quarter 2010 Financial Results 3BMP Sunstone Reports First Quarter 2010 Financial Results 4BMP Sunstone Reports First Quarter 2010 Financial Results 5BMP Sunstone Reports First Quarter 2010 Financial Results 6BMP Sunstone Reports First Quarter 2010 Financial Results 7BMP Sunstone Reports First Quarter 2010 Financial Results 8BMP Sunstone Reports First Quarter 2010 Financial Results 9BMP Sunstone Reports First Quarter 2010 Financial Results 10BMP Sunstone Reports First Quarter 2010 Financial Results 11BMP Sunstone Reports First Quarter 2010 Financial Results 12Dyadic International to Present at Rodman & Renshaw 6th Annual Global Healthcare Conference 2
(Date:3/31/2015)... YORK , March 31, 2015  Elephant Talk ... "Company"), a global provider of Software Defined Network Architecture ... today announced total revenue of approximately $20.4 million for ... a restated $19.5 million for the year ended December ... calendar 2014, the Company had completed its multi-year transition ...
(Date:3/26/2015)... TORONTO , March 26, 2015 ... premier family, social, recreation and athletic club, today announced ... designed to allow freedom of movement for members and ... "Following a comprehensive process, we selected FST,s IMID ... sophistication and convenience for our members and staff, in ...
(Date:3/24/2015)... 24, 2015   NexID Biometrics LLC, whose ... needs, today announced the beginning of shipments of version ... The company, based in Potsdam, N.Y. ... Connect:ID Expo, which began here today at the Walter ... 2.0 of its SDK boosts the accuracy rate range ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... Scientists at IRB Barcelona have discovered that some brain ... use the genetic programme of germline cells to grow. ... brains. This finding demonstrates that these genes are crucial for ... is published today in the prestigious journal Science . ...
... study was carried out to examine the extent ... or insulin resistance in primary cultures of human ... cytokine elevated in the plasma and adipose tissue ... adipocytes were pretreated with quercetin and trans-RSV followed ...
... have succeeded in plugging a metal atom into a ... could be a key in opening up new production ... of organic compounds, which in turn might have implications ... is the first to determine the precise structure of ...
Cached Biology News:Some brain tumors mimic the genetic program of germline cells 2Study on effects of resveratrol and quercetin on inflammation and insulin resistance 2Milestone: A methane-metal marriage 2Milestone: A methane-metal marriage 3Milestone: A methane-metal marriage 4
... P815 cells were cultured in DMEM and harvested ... order to keep the antigens in their native ... cells are arrayed on a 12-well (5 mm) ... treated to enhance cellular attachment and to minimize ...
... / 3T3 cells were cultured in DMEM with ... phase of growth. In order to keep ... fixed in acetone-methanol. The cells are arrayed ... with each wells surface specifically treated to enhance ...
Miscellaneous: Versatile stain for staining RNA (bluish-purple), DNA (blue), proteins (red) and acid polysaccharides Assay: ~ 95 % Suitab tst: differential staining of nucleic acids and prote...
... EPICENTREs patented MasterAmp™ 10X PCR ... performance and allows improved sensitivity and ... templates. Using MasterAmp PCR Enhancer in ... of DNA melting, increases enzyme?s thermal ...
Biology Products: